JH-RE-06|cas:1361227-90-8|西域试剂

JH-RE-06,99.87%

产品编号：Bellancom-126214| CAS NO：1361227-90-8| 分子式：C₂₀H₁₆Cl₃N₃O₄| 分子量：468.72

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-126214	￥3900.00	杭州北京（现货）
Bellancom-126214	￥7100.00	杭州北京（现货）
Bellancom-126214	￥12000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

JH-RE-06

产品介绍

JH-RE-06, 有效的 REV1-REV7 互作抑制剂 (IC₅₀=0.78 μM; K_d=0.42 μM)，靶向与 POLζ 的 REV7 亚基相互作用的 REV1。JH-RE-06 通过阻止诱变 POLζ 的募集来破坏诱变性跨损伤合成 (TLS)。JH-RE-06可改善化疗效果。

生物活性

JH-RE-06, a potent REV1-REV7 interface inhibitor (IC₅₀=0.78 μM; K_d=0.42 μM), targets REV1 that interacts with the REV7 subunit of POLζ. JH-RE-06 disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ. JH-RE-06 improves chemotherapy.

体外研究

JH-RE-06 unexpectedly induces dimerization of the REV1 CTD at its REV7-binding surface and blocks the REV1-REV7 interaction.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

JH-RE-06 inhibits mutagenic TLS and enhances cisplatin-induced toxicity in cultured human and mouse cell lines.
Co-administration of JH-RE-06 with cisplatin suppresses the growth of xenograft human melanomas in mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

性状

Solid

溶解性数据

In Vitro:

DMSO : 5 mg/mL (10.67 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1335 mL	10.6673 mL	21.3347 mL
5 mM	0.4267 mL	2.1335 mL	4.2669 mL
10 mM	0.2133 mL	1.0667 mL	2.1335 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式